Literature DB >> 25700835

Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.

Andrew Elson1, Joseph Bovi, Malika Siker, Chris Schultz, Eric Paulson.   

Abstract

To evaluate the association of normalized and absolute ADC metrics with progression free survival (PFS) and overall survival (OS) in patients treated for glioblastoma multiforme (GBM). Fifty-two patients with preradiotherapy diffusion weighted imaging treated with post-operative chemoradiation for GBM were evaluated. Region of interest analysis for ADC metrics including mean and minimum ADC value (ADCmean) and (ADCmin) was performed within the T2/FLAIR volume. Normalized (N)ADC values were generated relative to contralateral white matter. PFS and OS were analyzed relative to ADC parameters using a regression model. Kaplan-Meier and Cox proportional hazards analysis with respect to (N)ADCmean, and (N)ADCmin was performed. A (N)ADC threshold <1.3 within the T2/FLAIR volume was analyzed with respect to PFS and OS. Regression analysis indicated that normalized ADC values provide the strongest association with PFS and OS. Kaplan-Meier analysis revealed a non-significant trend toward inferior PFS and OS associated with (N)ADCmean <1.7, and a significant decrement to PFS and OS associated with (N)ADCmin <0.3. (N)ADCmin was a significant prognostic factor when taking into account age, performance status, and extent of resection. ADC thresholding analysis revealed that a retained volume of >0.45 cc per mL FLAIR volume was associated with a trend toward inferior PFS and OS. In the post-operative, pre-radiotherapy setting, the (N)ADCmin is the strongest predictor of outcomes in patients treated for GBM. ADC thresholding analysis indicates that a large volume of normalized ADC value <1.3 may be associated with adverse outcomes.

Entities:  

Mesh:

Year:  2015        PMID: 25700835     DOI: 10.1007/s11060-015-1743-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

Review 2.  Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond.

Authors:  Patric Hagmann; Lisa Jonasson; Philippe Maeder; Jean-Philippe Thiran; Van J Wedeen; Reto Meuli
Journal:  Radiographics       Date:  2006-10       Impact factor: 5.333

3.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Authors:  Ryuji Murakami; Takeshi Sugahara; Hideo Nakamura; Toshinori Hirai; Mika Kitajima; Yoshiko Hayashida; Yuji Baba; Natsuo Oya; Jun-Ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2007-03-13       Impact factor: 11.105

4.  Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.

Authors:  A Gupta; R J Young; A I Holodny; A B Lassman; S Karimi; S Sood; Z Zhang; Q Mo; P H Gutin
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

5.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Authors:  Suja Saraswathy; Forrest W Crawford; Kathleen R Lamborn; Andrea Pirzkall; Susan Chang; Soonmee Cha; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-09-23       Impact factor: 4.130

6.  Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Authors:  Joonmi Oh; Roland G Henry; Andrea Pirzkall; Ying Lu; Xiaojuan Li; Isabelle Catalaa; Susan Chang; William P Dillon; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2004-05       Impact factor: 4.813

Review 7.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?

Authors:  Hideo Nakamura; Ryuji Murakami; Toshinori Hirai; Mika Kitajima; Yasuyuki Yamashita
Journal:  Acta Radiol       Date:  2012-11-08       Impact factor: 1.990

10.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Authors:  Forrest W Crawford; Inas S Khayal; Colleen McGue; Suja Saraswathy; Andrea Pirzkall; Soonmee Cha; Kathleen R Lamborn; Susan M Chang; Mitchel S Berger; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-11-15       Impact factor: 4.130

View more
  13 in total

1.  Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.

Authors:  Kunal S Patel; Richard G Everson; Jingwen Yao; Catalina Raymond; Jodi Goldman; Jacob Schlossman; Joseph Tsung; Caleb Tan; Whitney B Pope; Matthew S Ji; Nhung T Nguyen; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Neurosurgery       Date:  2020-10-15       Impact factor: 4.654

2.  Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.

Authors:  Lei Qin; Xiang Li; Amanda Stroiney; Jinrong Qu; Jeffrey Helgager; David A Reardon; Geoffrey S Young
Journal:  Neuroradiology       Date:  2017-01-09       Impact factor: 2.804

Review 3.  Diffusion imaging could aid to differentiate between glioma progression and treatment-related abnormalities: a meta-analysis.

Authors:  Rik van den Elshout; Tom W J Scheenen; Chantal M L Driessen; Robert J Smeenk; Frederick J A Meijer; Dylan Henssen
Journal:  Insights Imaging       Date:  2022-10-04

Review 4.  Supramarginal Resection for Glioblastoma: It Is Time to Set Boundaries! A Critical Review on a Hot Topic.

Authors:  Francesco Guerrini; Elena Roca; Giannantonio Spena
Journal:  Brain Sci       Date:  2022-05-16

5.  Integrated MRI-Immune-Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma.

Authors:  Giulia Mazzaschi; Alessandro Olivari; Antonio Pavarani; Costanza Anna Maria Lagrasta; Caterina Frati; Denise Madeddu; Bruno Lorusso; Silvia Dallasta; Chiara Tommasi; Antonino Musolino; Marcello Tiseo; Maria Michiara; Federico Quaini; Pellegrino Crafa
Journal:  Cancers (Basel)       Date:  2022-07-01       Impact factor: 6.575

6.  Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

Authors:  Akifumi Hagiwara; Talia C Oughourlian; Nicholas S Cho; Jacob Schlossman; Chencai Wang; Jingwen Yao; Catalina Raymond; Richard Everson; Kunal Patel; Sergey Mareninov; Fausto J Rodriguez; Noriko Salamon; Whitney B Pope; Phioanh L Nghiemphu; Linda M Liau; Robert M Prins; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

7.  Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma.

Authors:  Daniel Jeong; Christian Malalis; John A Arrington; Aaron S Field; Jung W Choi; Mehmet Kocak
Journal:  Quant Imaging Med Surg       Date:  2015-12

8.  Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG).

Authors:  Lei Qin; Angie Li; Jinrong Qu; Katherine Reinshagen; Xiang Li; Su-Chun Cheng; Annie Bryant; Geoffrey S Young
Journal:  J Neurooncol       Date:  2018-01-30       Impact factor: 4.130

9.  Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement.

Authors:  Nicholas Cho; Chencai Wang; Catalina Raymond; Tania Kaprealian; Matthew Ji; Noriko Salamon; Whitney B Pope; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2020-04-01       Impact factor: 4.130

10.  Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Authors:  Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung
Journal:  Med Phys       Date:  2021-05-20       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.